Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Subcutaneous Blinatumomab Plus Ponatinib for BCR-ABL Positive B-ALL
NCT07301424Phase 2Not yet recruiting
- Sponsor
- University of Alberta
- Start
- Jan 2027
- Primary completion
- Dec 2027
- Modality
- Antibody Conjugates, scFv Fragments, Bispecific Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of blinatumomab in acute lymphoblastic leukemia (ALL), sponsored by University of Alberta. Planned start Jan 2027; status: not yet recruiting.
02
Drugs
blinatumomab
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT07301424.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07301424.